Epidemiological Profile and Therapeutic Results of Brain Metastases after Encephalic Radiotherapy in Toto

M Zaouit*, N Benchakroun, Z Bouchbika, H Jouhadi, N Tawfiq, S Sahraoui, and A Benider

Mohamed VI Center for Cancer Treatment, Casablanca, Morocco

*Corresponding author: Maryam ZAOUIT, Mohamed VI Center for Cancer Treatment, Casablanca, Morocco

ABSTRACT

Brain metastases are considered to be the most common malignant brain tumors in adults, and constitute a major challenge in oncology. The objective of our study is to analyze the epidemiological, clinical and paraclinical parameters of patients with brain metastases and treated by encephalic radiotherapy during the year 2020 at the Mohamed VI center of the Ibn Rochd CHU.

Patients and Methods

This is a descriptive retrospective study of 57 patients treated for brain metastases by brain radiotherapy in toto over a period of one year from January 2020 to December 2020 at the Mohamed VI center for the treatment of cancers. Data was collected using a form duly completed from patient files.

Results

The median age was 54 years with extremes ranging from 33 to 79 years, a female predominance was noted with a sex ratio of 1.11. The evaluation of the general condition made it possible to classify the patients of performance index status ‘1’ in 75.4% of cases. 70.2% of cases had multiple brain metastases, 26.3% of cases had a single metastasis and 2 cases had three brain lesions (Figure 1). The primary was of bronchopulmonary origin in 57.9% of cases, of mammary origin in 38.6% of cases, and of renal origin in 2 cases (Figure 2). The discovery of brain metastases was synchronous with that of the primary in 49% of cases and metachronous in the rest of the cases.

Most patients showed signs of brain extension at the time of diagnosis. 35% of the patients suffered from a neurological deficit and 47.4% from an intracranial hypertension syndrome. However, the discovery of secondary cerebral localization was fortuitous in 10 cases. 52.6% of cases had other metastatic sites (Bone, Lung).

Accepted: June 29, 2022; Published: June 30, 2022
Copyright: © 2022 Zaouit M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Complete response without local recurrence. 15.7% of cases worsened their neurological symptoms and 10.5% of patients were lost to follow-up after the end of brain radiation therapy. The median survival time was 5.2 months that of recurrence-free survival of the five operated patients was 7.8 months.

Conclusion

The characteristics of cerebral metastases and the type of primary cancer are an important determinant for the prognosis; therapeutic management must take into account the predictive criteria for local control; and the early detection of this pejorative localization.

All patients underwent 3D conformational radiotherapy of the brain in toto with a dose of 30 Gy in 10 fractions in 15.8% of cases, 20 Gy in 4 to 5 fractions in 79% of cases and 16 Gy in 4 fractions in 3 cases. An additional boost of 3 * 3 Gy was received in 4 patients. However, surgical excision before radiotherapy was only performed in 5 cases (Figure 3).

All symptomatic patients were put on corticosteroid therapy initially by the injectable route for three days then relayed by the oral route.

At the evaluation; 54.4% of patients improved their quality of life with a recovery of their autonomy and an improvement in verbal fluency. 19.3% of cases had a complete response without local recurrence. 15.7% of cases worsened their neurological symptoms and 10.5% of patients were lost to follow-up after the end of brain radiation therapy.

The median survival time was 5.2 months that of recurrence-free survival of the five operated patients was 7.8 months.

Figure 2: Main primitive sites

Figure 3: Main therapeutic protocols